Literature DB >> 23524863

Poly (ADP-ribose) polymerase (PARP) inhibitors for the treatment of advanced germline BRCA2 mutant prostate cancer.

S K Sandhu, A Omlin, L Hylands, S Miranda, L J Barber, R Riisnaes, A H Reid, G Attard, L Chen, I Kozarewa, H Gevensleben, J Campbell, K Fenwick, I Assiotis, D Olmos, T A Yap, P Fong, N Tunariu, D Koh, L R Molife, S Kaye, C J Lord, A Ashworth, J de Bono.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23524863     DOI： 10.1093/annonc/mdt074

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  28 in total

1.  DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.

Authors:  Joaquin Mateo; Suzanne Carreira; Shahneen Sandhu; Susana Miranda; Helen Mossop; Raquel Perez-Lopez; Daniel Nava Rodrigues; Dan Robinson; Aurelius Omlin; Nina Tunariu; Gunther Boysen; Nuria Porta; Penny Flohr; Alexa Gillman; Ines Figueiredo; Claire Paulding; George Seed; Suneil Jain; Christy Ralph; Andrew Protheroe; Syed Hussain; Robert Jones; Tony Elliott; Ursula McGovern; Diletta Bianchini; Jane Goodall; Zafeiris Zafeiriou; Chris T Williamson; Roberta Ferraldeschi; Ruth Riisnaes; Bernardette Ebbs; Gemma Fowler; Desamparados Roda; Wei Yuan; Yi-Mi Wu; Xuhong Cao; Rachel Brough; Helen Pemberton; Roger A'Hern; Amanda Swain; Lakshmi P Kunju; Rosalind Eeles; Gerhardt Attard; Christopher J Lord; Alan Ashworth; Mark A Rubin; Karen E Knudsen; Felix Y Feng; Arul M Chinnaiyan; Emma Hall; Johann S de Bono
Journal:  N Engl J Med       Date:  2015-10-29       Impact factor: 91.245

2.  Cancer genomics and inherited risk.

Authors:  Zsofia K Stadler; Kasmintan A Schrader; Joseph Vijai; Mark E Robson; Kenneth Offit
Journal:  J Clin Oncol       Date:  2014-01-21       Impact factor: 44.544

Review 3.  Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017.

Authors:  Veda N Giri; Karen E Knudsen; William K Kelly; Wassim Abida; Gerald L Andriole; Chris H Bangma; Justin E Bekelman; Mitchell C Benson; Amie Blanco; Arthur Burnett; William J Catalona; Kathleen A Cooney; Matthew Cooperberg; David E Crawford; Robert B Den; Adam P Dicker; Scott Eggener; Neil Fleshner; Matthew L Freedman; Freddie C Hamdy; Jean Hoffman-Censits; Mark D Hurwitz; Colette Hyatt; William B Isaacs; Christopher J Kane; Philip Kantoff; R Jeffrey Karnes; Lawrence I Karsh; Eric A Klein; Daniel W Lin; Kevin R Loughlin; Grace Lu-Yao; S Bruce Malkowicz; Mark J Mann; James R Mark; Peter A McCue; Martin M Miner; Todd Morgan; Judd W Moul; Ronald E Myers; Sarah M Nielsen; Elias Obeid; Christian P Pavlovich; Stephen C Peiper; David F Penson; Daniel Petrylak; Curtis A Pettaway; Robert Pilarski; Peter A Pinto; Wendy Poage; Ganesh V Raj; Timothy R Rebbeck; Mark E Robson; Matt T Rosenberg; Howard Sandler; Oliver Sartor; Edward Schaeffer; Gordon F Schwartz; Mark S Shahin; Neal D Shore; Brian Shuch; Howard R Soule; Scott A Tomlins; Edouard J Trabulsi; Robert Uzzo; Donald J Vander Griend; Patrick C Walsh; Carol J Weil; Richard Wender; Leonard G Gomella
Journal:  J Clin Oncol       Date:  2017-12-13       Impact factor: 44.544

4.  Base excision repair defects invoke hypersensitivity to PARP inhibition.

Authors:  Julie K Horton; Donna F Stefanick; Rajendra Prasad; Natalie R Gassman; Padmini S Kedar; Samuel H Wilson
Journal:  Mol Cancer Res       Date:  2014-04-25       Impact factor: 5.852

5.  PARP-1 regulates epithelial-mesenchymal transition (EMT) in prostate tumorigenesis.

Authors:  Hong Pu; Craig Horbinski; Patrick J Hensley; Emily A Matuszak; Timothy Atkinson; Natasha Kyprianou
Journal:  Carcinogenesis       Date:  2014-08-30       Impact factor: 4.944

Review 6.  The genetic epidemiology of prostate cancer and its clinical implications.

Authors:  Rosalind Eeles; Chee Goh; Elena Castro; Elizabeth Bancroft; Michelle Guy; Ali Amin Al Olama; Douglas Easton; Zsofia Kote-Jarai
Journal:  Nat Rev Urol       Date:  2013-12-03       Impact factor: 14.432

Review 7.  Drug discovery in advanced prostate cancer: translating biology into therapy.

Authors:  Timothy A Yap; Alan D Smith; Roberta Ferraldeschi; Bissan Al-Lazikani; Paul Workman; Johann S de Bono
Journal:  Nat Rev Drug Discov       Date:  2016-07-22       Impact factor: 84.694

Review 8.  DNA damage response and prostate cancer: defects, regulation and therapeutic implications.

Authors:  S Karanika; T Karantanos; L Li; P G Corn; T C Thompson
Journal:  Oncogene       Date:  2014-08-18       Impact factor: 9.867

Review 9.  Targeting the androgen receptor pathway in castration-resistant prostate cancer: progresses and prospects.

Authors:  R Ferraldeschi; J Welti; J Luo; G Attard; J S de Bono
Journal:  Oncogene       Date:  2014-05-19       Impact factor: 9.867

10.  Inherited Mutations in Men Undergoing Multigene Panel Testing for Prostate Cancer: Emerging Implications for Personalized Prostate Cancer Genetic Evaluation.

Authors:  Veda N Giri; Elias Obeid; Laura Gross; Lisa Bealin; Colette Hyatt; Sarah E Hegarty; Susan Montgomery; Andrea Forman; Ruth Bingler; William K Kelly; Adam P Dicker; Stephanie Winheld; Edouard J Trabulsi; David Y T Chen; Costas D Lallas; Brian A Allen; Mary B Daly; Leonard G Gomella
Journal:  JCO Precis Oncol       Date:  2017-05-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.